Important Notice Regarding Alleged TNX-103 Efficacy Misrepresentations: the lawsuit claims Tenax promoted its Phase 3 LEVEL study as "derisked" while its lead drug candidate was allegedly less effective than represented.
NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Tenax Therapeutics, Inc. (NASDAQ: TENX) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between November 13, 2023 and August 7, 2026. Find out if you could qualify to recover your losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
Nearly 90% of Tenax's market value was erased in a single session after its lead candidate, TNX-103 (levosimendan), failed a pivotal Phase 3 trial. A biotech securities fraud lawsuit now alleges that the Company overstated the drug's efficacy and, according to the lawsuit, collected roughly $134 million in gross proceeds from a public offering and private placements during the Class Period while promoting the program as "derisked." Applications to serve as lead plaintiff must be filed by December 28, 2026.
The Alleged "Derisked" Methodology Behind TNX-103
Tenax is a cardiopulmonary drug developer based in Chapel Hill, North Carolina. It aimed TNX-103 at pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), a disease the Company said had no FDA-approved drugs. The complaint alleges that management repeatedly told the market the LEVEL study was derisked, citing Phase 2 data, a patient-enrichment design, and levosimendan's approved use in other conditions.
The lawsuit contends that TNX-103 was in fact less effective than investors had been led to believe.
Key TNX-103 Efficacy Securities Fraud Allegations for Shareholders
- Phase 2 as proof: Management allegedly pointed to Phase 2 HELP results as evidence that TNX-103 would improve six-minute walk distance, the same primary endpoint chosen for Phase 3.
- Patient enrichment: LEVEL was allegedly enriched with patients resembling Phase 2 responders, a design presented as improving the odds of a favorable response.
- Oral dosing confidence: Investors were allegedly told that daily oral dosing should perform better than the weekly intravenous regimen studied in Phase 2.
- Upsized study: The Company expanded LEVEL to a 230-patient target and said the study's statistical power exceeded 95%.
- Core claim: The complaint alleges that the Company's statements about TNX-103's efficacy and clinical prospects were materially false and misleading throughout the Class Period.
The Single-Asset Factor
The Company suspended a planned Phase 3 trial of its other candidate, imatinib, so it could prioritize LEVEL. That decision placed TNX-103 at the center of Tenax's pipeline and gave efficacy disclosures outsized weight in how shareholders valued the stock.
"This case presents important questions about efficacy disclosure obligations in the clinical-stage biotech sector, where a single Phase 3 readout can decide a company's future. The complaint alleges that shareholders were assured the LEVEL study was derisked while TNX-103 was less effective than represented," said Joseph E. Levi, Esq., managing partner of Levi & Korsinsky, LLP.
Submit your information here or call (212) 363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the TENX Lawsuit
Q: Who is eligible to join the TENX investor lawsuit? A: Investors who purchased TENX stock or securities between November 13, 2023 and August 7, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.
Q: What specific misstatements does the TENX lawsuit allege? A: The complaint alleges that Tenax Therapeutics, Inc. made materially false or misleading statements during the Class Period regarding the efficacy and clinical prospects of TNX-103, including representations that its Phase 3 LEVEL study was "derisked." When the Company disclosed that the LEVEL trial had failed to meet its primary and key secondary endpoints, the stock price declined sharply.
Q: What court was the TENX class action filed in? A: The case was filed in the United States District Court for the Middle District of North Carolina, governed by the Private Securities Litigation Reform Act of 1995.
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: What happens after I contact Levi & Korsinsky? A: An attorney will review your trading history at no cost and provide an initial assessment of your potential eligibility.
Q: What if I already sold my TENX shares? Can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Securities class actions are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.

